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There is increased investigation of the human microbiome as it relates to health and disease. Dysbiosis is implicated in various
clinical conditions including inﬂammatory bowel disease (IBD). Probiotics have been explored as a potential treatment for IBD
and other diseases. The mechanism of action for probiotics has yet to be fully elucidated. This paper discusses novel mechanisms
of action for probiotics involving anti-inﬂammatory signaling pathways. We highlight recent progress in probiotics and nuclear
receptor signaling, such as peroxisome-proliferator-activated receptor gamma (PPARγ)a n dv i t a m i nDr e c e p t o r( V D R ) .W ea l s o
discuss future areas of investigation.
1.Introduction
Probiotics are ingestible microorganisms with health bene-
ﬁts. Increased interest in the intestinal microbiome and its
eﬀect on health and disease is evidenced by the concomi-
tant increase in peer-reviewed clinical trials investigating
probiotics as therapy since 1999 [1]. Studies of the various
signaling pathways involved in the response to bacteria and
inﬂammation have led to a more detailed understanding of
mechanisms and actions of probiotics. This paper discusses
progress in understanding how probiotics contribute to
intestinal mucosal function, particularly in relation to anti-
inﬂammatory signaling pathways.
2. Intestinal Microﬂora
The intestinal microﬂora, as a whole, serves important
functions in metabolism, intestinal epithelial cell function
and health, immunity, and inﬂammatory signaling [2, 3].
Recently, there has been increasing interest in the role of
the intestinal microﬂora and its total genetic composition,
together referred to as the microbiome in the development,
maintenance, and perpetuation of various clinical condi-
tions, both intestinal and extraintestinal.
Dysbiosis has been implicated in various clinical condi-
tions including atopy, irritable bowel syndrome (IBS), col-
orectal cancer, alcoholic liver disease in animal and human
studies, obesity and other metabolic disorders, and chronic
inﬂammatory diseases such as IBD [4–11]. Decreased
diversity of the intestinal microbiota was seen in fecal
samplesobtainedfromchildrenwhosubsequentlydeveloped
allergic disease [6, 7]. Altered microbiota composition in
colon cancer patients when compared to patients with
normal colonoscopies and in patients with IBS compared
to unaﬀected patients has also been demonstrated [5, 9].
Alcohol feeding resulted in enteric bacterial overgrowth in
am o u s em o d e l[ 8]. The role of the microbiota in obesity
has been extensively studied and carefully reviewed in the
literature [12, 13]. Microbial composition in IBD patients
with ulcerative colitis (UC) or Crohn’s disease (CD) as com-
pared to unaﬀected individuals has been studied and shows
decreased diversity [4, 14–19]. This altered microﬂora may
have signiﬁcant implications for the intestinal milieu, with as
yetincompletelyunderstoodeﬀects.ThepathogenesisofIBD2 Gastroenterology Research and Practice
likely involves a combination of factors including intestinal
dysbiosis in conjunction with environmental factors in a
genetically susceptible host [20].
Based on the concept of a dysregulated or dysfunctional
microbiota in disease, various methods to attenuate the
eﬀects of an altered microbiome have been attempted.
3. Probiotics
“Probiotics” were ﬁrst described in the literature by Lilly
and Stillwell in 1965 as growth-promoting factors produced
by certain microorganisms [21] although it may have been
described as early as 1908 [22]. Recently, probiotics were
deﬁned as “live organisms which, when consumed in ade-
quate amounts as part of food, confer a health beneﬁt on the
host” (Report of a Joint FAO/WHO Expert Consultation on
EvaluationofHealthandNutritionalPropertiesofProbiotics
in Food Including Powder Milk with Live Lactic Acid
Bacteria (October 2001), “Health and Nutritional Properties
of Probiotics in Food Including Powder Milk with Live
Lactic Acid Bacteria”, Food and Agriculture Organization
of the United Nations, World Health Organization). The
mechanisms of action of probiotics include immune modu-
lation,directeﬀectoncommensalandpathogenicbacteriato
inhibit infection and restore homeostasis, and modiﬁcation
of pathogenic toxins and host products [23]. The eﬃcacy of
probiotics in various clinical conditions both in the pediatric
and adult patient population has been extensively studied
and carefully reviewed [1, 19, 24–32].
Rectal infusion of normal stool via enemas to treat
pseudomembranous colitis has been described as early as
1958 [70]. Infusion of stool via nasogastric tube to the
small intestine or via colonoscopy to the colon for CDAD
has also been described and shows high response rates
[71–74]. A recent study showed that fecal bacteriotherapy
was eﬀective in relief of clinical symptoms in a patient
with recurrent CDAD and that this was accompanied by
the repopulation of the diseased intestinal microbiota with
beneﬁcial species that were diminished pretreatment [75].
Other methods to supply live, nonpathogenic organisms to
the intestinal microbiota in AAD and CDAD include orally
administered probiotics. The eﬃcacy of various probiotic
formulations in AAD and CDAD has been extensively
studied and carefully reviewed [1]. A recent study showed
that the probiotics Lactobacillus acidophilus and Lactobacillus
casei were well tolerated and eﬀective in reducing the
risk of the development of AAD and CDAD [76]. The
utility of the probiotic yeast Saccharomyces boulardii for a
variety of conditions including traveler’s diarrhea, enteral
nutrition-associated diarrhea, AAD, and CDAD has been
investigated, and according to a recent meta-analysis, strong
evidence exists for advocating its use in traveler’s diarrhea
and AAD [77]. Recent trials using Biﬁdobacterium biﬁdum
and Saccharomyces boulardii demonstrated improvement in
clinical IBS symptoms and quality of life [78, 79], and several
reviews of the evidence for the utility of probiotics in IBS
have been published [80–82].
For IBD therapy, treatment with diﬀerent strains of
probiotics has shown varied results. Small trials have shown
promise for probiotic use in the induction and maintenance
of remission in UC. VSL#3 has been shown to be safe and
eﬀective in the treatment of acute mild to moderately active
UC [83]. Patients with mild to moderate UC unresponsive to
conventional therapy achieved a combined induction remis-
sion/response rate of 77% with treatment with VSL#3 [84].
E. coli Nissle 1917 was found to be eﬀective and equivalent to
mesalazine in maintaining remission in UC [85]. In another
study, Lactobacillus rhamnosus GG (LGG) was equivalent to
mesalazine in the maintenance of remission in UC, however,
appeared to be more eﬀective in prolonging the relapse-
free time [86]. Evidence also exists for the role of probiotics
in prophylaxis of pouchitis after surgery in UC patients
as well as induction of remission in chronic pouchitis
[87, 88].
Studies of probiotic use in induction and maintenance
of remission and prevention of postoperative recurrence
in CD have been less consistent than those for UC. A
small study of LGG for the prevention of recurrence after
surgery in CD did not show any improvement over placebo
[89]; however, Saccharomyces boulardii appears useful in
maintaining remission in CD [90, 91] .T h ep r o g r e s si nt h e
useofprobioticsforIBDhasbeencarefullyreviewed[92,93];
however, there remains a relative lack of well-designed, large,
randomized, placebo-controlled trials.
Several barriers exist to advocating broad use of probi-
oticsinclinicalpractice,notleastofwhichistheconsiderable
heterogeneity in the experimental designs with respect to
species and strains of probiotics and the various animal
models utilized [94]. Although clinical trials examining the
roleofprobioticsinthetreatmentand/orpreventionofAAD,
CDAD, IBD including UC, CD, and pouchitis, necrotizing
enterocolitis, infectious gastroenteritis, radiation-induced
enteritis, and colitis, IBS and various atopic diseases have
been reported [1, 24, 25, 28, 29, 31, 87, 95–97]; in many
cases,resultshavebeeninconsistent,andlarge,well-designed
trials are lacking. An additional complicating factor pertains
to issues of quality control. Determining whether a commer-
cially available probiotic actually contains the live organisms
it purports to contain and determining if there is rational
selection of component probiotic strains in “cocktails” are
issues that must be considered [22]. Future research to reﬁne
techniques to accurately identify “normal” and “diseased”
microbiota and to further elucidate the speciﬁc eﬀects and
mechanismsofactionsofindividualprobioticstrainswillaid
in optimizing therapeutic eﬃcacy.
4. Mechanisms for Probiotics in
Anti-Inﬂammation
There has been and continues to be considerable research in
delineating the underlying mechanisms by which probiotics
exert their beneﬁcial eﬀects. The mechanisms regulating the
functionofprobiotics arevery diverse. It is wellacceptedthat
probiotics use distinct cellular and molecular mechanisms,
including blocking pathogenic bacterial eﬀects, regulat-
ing immune responses, and altering intestinal epithelial
homeostasis by promoting cell survival, enhancing barrier
function, and stimulating protective responses [32].Gastroenterology Research and Practice 3
Table 1 outlines representative publications on probiotic
mechanisms of actions. The probiotic-host interaction is
complex and further complicated by the fact that certain
probiotic eﬀects appear to be species and strain speciﬁc.
Diﬀerent probiotics have been shown to exert both pro-
inﬂammatory [98] and anti-inﬂammatory eﬀects on den-
dritic cells [99]. A recent study demonstrated that the anti-
inﬂammatory eﬀect of certain lactobacilli is via NOD2-
mediated signaling [100]. NOD2/CARD15 is a member of
a superfamily of genes involved in intracellular bacterial
recognition and has been identiﬁed as an important suscep-
tibility gene for CD [101, 102]. The authors speculate that
the inconsistent clinical results of lactobacilli use in patients
with CD may be related to a relative deﬁciency of NOD2.
Probiotic eﬀect on the innate immune responsive pathways
including toll-like receptor (TLR), nuclear factor kappa B
(NF-κB), mitogen-activated protein kinase (MAPK), c-Jun
NH2-terminalkinase(JNK)hasbeenextensivelyinvestigated
(Table 1). Activation of speciﬁc TLRs also appears to be
species speciﬁc [47, 48]. The action of E. coli Nissle 1917 on
Caco-2 cells was found to be mediated by ﬂagellin possibly
viaaTLRpathway[103].Theprobiotic-inducedeﬀectonthe
NF-κB signaling pathway is well represented in the literature
and is generally characterized by inhibition (Table 1).
Defective epithelial barrier function has been implicated
in IBD and can predict relapse during clinical remission
[104–109]. One way by which probiotics have been shown
exert their action is by stabilizing tight junctions (TJs)
and enhancing barrier function of intestinal epithelial cells
(Table 1).
Abnormal STAT/suppressor of cytokine signaling
(SOCS) signaling has been demonstrated in CD patients
[110], and probiotics are also shown to modulate the JAK-
STAT signaling in human placental trophoblast cells [111].
Increasing evidence further demonstrates that metabolism,
xenobiotics, and nuclear receptor signaling are involved in
the action of probiotics [67, 68].
Inductionofheatshockproteins(HSPs)andendogenous
antimicrobial peptides (defensins) via activation of NF-κB,
MAPK, and JNK has also been linked to probiotic action [35,
41, 43]. Since defensins are implicated in the pathogenesis of
IBD, increased expression by probiotics provides a possible
mechanism for clinical eﬃcacy seen in certain IBD patients
and deserves further study.
5. Defensins andNuclearReceptor Signaling
Defensins are a class of endogenous antimicrobial peptides
involved in innate immunity which is highly evolutionarily
conserved and represents a primary line of defense against
various microbial pathogens [112–114]. Antimicrobial pep-
tides are widely distributed throughout the animal and plant
kingdom, and despite their evolutionary heritage, remain
eﬀective antimicrobial agents [114]. This is due, in large
part, to their mechanism of action involving membrane
disruption and pore formation, which is not easily exploited
by pathogens to confer resistance [112–115]. Important
antimicrobial peptides in humans include defensins, cathe-
licidins, lysozymes, and other antimicrobial antiproteases
[116]. There are three known defensin subfamilies; α and β
defensinsareexpressedmainlyinimmunecellsandepithelial
cells while the θ defensin is found mainly in immune cells
of the Rhesus macaque [117, 118]. In the gastrointestinal
tract, β defensin expression is seen in multiple sites, whereas
α defensin expression is largely in the small intestine
[119]. In the uninﬂamed colon, human β defensin 1 is
the predominant defensin and human β defensin 2 and 3
are induced with inﬂammation or infection [120]. In mice
lackingfunctionalcryptidins(murineαdefensins),increased
survival and virulence of orally administered bacteria were
seen and intestinal peptide preparations had decreased
antimicrobial activity [121].
The possible role of a deﬁciency in defensins in the
pathogenesis of IBD has been proposed [116, 122]. The
Paneth cells of the small intestine are the major source of
endogenous antimicrobials, including α defensins [102]. In
addition,ThePanethcellshavebeenshowntoexpressNOD2
[123]. In patients with ileal CD, human α defensin 5 and
6 production is reduced, and this eﬀect is magniﬁed in
those patients with a concomitant NOD2 mutation [124].
For β defensins, CD patients with colonic disease exhibit
normal levels of β defensin 2 and 3 whereas UC patients
haveincreasedlevels,suggestingaroleoffailureofβ defensin
induction in the pathogenesis of CD [125]. Constitutive
human β defensin 1 expression is reduced in CD patients
with colonic involvement independent of inﬂammation,
and recently, the maintenance of constitutive β defensin
expression was shown to be activated by the nuclear receptor
peroxisome-proliferator-activated receptor gamma (PPARγ)
[122].
Further contributing to the eﬀect of a defensin deﬁ-
ciency in the pathogenesis of IBD may be the diminished
diversity of the intestinal microbiota seen in IBD patients.
The interaction of commensal bacteria with antimicrobial
peptide synthesis is not well understood; however, it has
been suggested that commensal bacteria provide chronic
stimulation of epithelial cells to produce antimicrobial
peptides at levels suﬃcient to kill microbial pathogens [114,
126].
Probiotics, but not fecal isolates, have been shown to
induce human β defensin 2 in intestinal epithelial cells [41,
42]. Wehkamp et al. and Schlee et al. have reported that
NF-κB and activator protein-1 (AP-1) mediate induction
of human β defensin 2 in intestinal epithelial cells by the
probiotic E. coli Nissle 1917 and VSL#3 [41, 42].
Interestingly, nuclear receptors are known to regulate the
expressions of defensins [122, 127]. Nuclear receptors rep-
resent a class of intracellular transcription factors activated
by ligands which can directly interact with DNA; as a result,
nuclear receptors play signiﬁcant roles in the regulation of
metabolic, reproductive, developmental, and immune pro-
cesses [128–131]. Nuclear receptors regulate transcriptional
activity by several distinct mechanisms, including “ligand-
dependent transactivation, ligand-independent repression,
and ligand-dependent transrepression” although the range
of transcriptional activities of each nuclear receptor varies
and even the transcriptional eﬀects of a single nuclear











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































]10 Gastroenterology Research and Practice
of nuclear receptors and their mechanisms of action is
beyond the scope of this article; however, further discussion
of two nuclear receptors (peroxisome-proliferator-activated
receptor gamma (PPARγ) and vitamin D receptor (VDR))
with putative roles in inﬂammation is warranted.
PPARγ is a member of a class of nuclear receptors that
form obligate heterodimers with the retinoid X receptor
(RXR) [129]. The PPAR family has been shown to aﬀect
various cellular functions including “adipocyte diﬀerentia-
tion, fatty-acid oxidation, and glucose metabolism” [129].
PPARγ is highly expressed in the large intestine [133], and its
activation has been shown to be protective in animal models
of colitis [134, 135]. Decreased PPARγ expression in UC
patients has been shown [136], and the anti-inﬂammatory
compound 5-aminosalicylic acid (5-ASA) commonly uti-
lized in IBD therapy was shown to be a PPARγ agonist,
thereby establishing a possible mechanism by which it exerts
its anti-inﬂammatory eﬀects [137]. PPARγ also plays a role
in the maintenance of “constitutive epithelial expression of a
subset of β defensins in the colon” [122].
6.VitaminDandVitaminDReceptor (VDR)
Vitamin D receptor (VDR) is a nuclear receptor that medi-
ates most known functions of 1,25-dihydroxyvitamin D
(1,25(OH)2D3), the active form of vitamin D [138]. VDR
heterodimerizes with RXR once VDR is activated by
1,25(OH)2D3. VDR binds tothe vitamin D response element
in the target gene promoter to regulate gene transcription
[139]. VDR downstream target genes include antimicrobial
peptides such as cathelicidin and β defensin.
VDR is critical in regulating intestinal homeostasis by
preventing pathogenic bacterial invasion, inhibiting inﬂam-
mation, and maintaining cell integrity [140–145]. Vitamin
D directly modulates the T-cell receptor (TCR) [146], and
vitamin D has also been shown to downregulate the expres-
sion of proinﬂammatory cytokines and have regulatory
eﬀects on autophagy and various immune cells including
T cells, B cells, macrophages, dendritic cells, and epithelial
cells [147, 148]. It has been reported that 1,25(OH)2D3
suppresses the development of IBD in animal models [149].
Deﬁciency of 1,25(OH)2D3 has been reported in patients
with IBD [150, 151], and, recently, using a novel vitamin D
bioavailability test, vitamin D deﬁciency or insuﬃciency was
seen in more than 70% of patients with quiescent CD [152].
Given the diverse immune functions of vitamin D, deﬁcient
levels may have important implications for the development
and maintenance of intestinal homeostasis. A possible role
of vitamin D status and VDR signaling in modulating the
eﬀects of intestinal microﬂora in other conditions such
as asthma and obesity has been suggested [100]. While
present literature has primarily focused on elucidating the
immunoregulatory eﬀects of vitamin D, there is a paucity of
data on the status and function of VDR [147]. In addition,
probiotic-induced modulation of anti-inﬂammatory VDR
signaling in colitis remains virtually unexplored.
Recent studies indicate that VDR−/− mice have
increased bacterial loading in the intestine [145, 153]. Our
microarray data found that VDR signaling responds to
pathogenic Salmonella in intestinal colitis in vivo [154]. Data
from a recent study demonstrate that bacterial stimulation,
both commensal and pathogenic, regulates VDR expression
and location and that VDR negatively regulates bacterial-
induced intestinal NF-κBa c t i v a t i o n[ 153]. In general,
probiotic-inducednuclearreceptorsignalingisnotwellchar-
acterized. The probiotic VSL3# was associated with nuclear
receptorsignalingintheIL10−/−colitismodel[67].Nuclear
receptors have been shown to negatively regulate bacterial-
stimulatedNF-κBactivityinintestinalepithelium[153,155].
Our recent data show probiotic treatment is able to enhance
VDR expression and activity in the host. An increase in
VDR expression and a concomitant increase in cathelicidin
mRNA in cultured intestinal epithelial cells when treated
with Lactobacillus plantarum were seen [156]. We used a
probiotic monoassociated pig model to assess the probiotic
eﬀect on VDR expression in vivo and found intestinal VDR
increased signiﬁcantly after probiotic colonization compared
to the ex-germ-free pig. Furthermore, our unpublished data
indicate that probiotics did not inhibit inﬂammation in mice
lacking VDR.
The presence of VDR in various tissues along with its
ability to exert diverse actions in diﬀerentiation, growth, and
anti-inﬂammation sets the stage for exploitation of VDR
ligandsforthetreatmentofvariousinﬂammatoryconditions
[157, 158]. Although the potential importance of VDR as a
therapeutic target has been appreciated [159], no approach
to date has safely and eﬀectively altered VDR’s activity.
Hence, understanding VDR’s contribution to probiotic-
induced anti-inﬂammation may provide signiﬁcant insight
in the pathogenesis of inﬂammatory conditions such as IBD,
and thereby, guide the development of novel treatments.
Further investigation of the complex interplay of nuclear
receptors, defensins, probiotics, and inﬂammatory pathways
may provide signiﬁcant insight into the mechanisms of
action of probiotics in anti-inﬂammation.
7. Current Problems and Future Directions
The individual diversity of the intestinal microﬂora under-
scores the diﬃculty of identifying the entire human micro-
biota and poses barriers to this ﬁeld of research. In addition,
it is apparent that the actions of probiotics are species and
strainspeciﬁc[19].Itisalsoapparentthatevenasinglestrain
of probiotic may exert its actions via multiple, concomitant
pathways. Current investigation into the mechanism of
action of speciﬁc probiotics has focused on probiotic-
induced changes in the innate immune functions involving
TLRs and its downstream systems including NF-κB, JAK-
STAT, MAPK, and SAPK/JNK pathways. Future research on
novel mechanisms of action for probiotics involving nuclear
receptor signaling, including PPARγ and VDR, is needed.
With evolving knowledge, eﬀective probiotic therapy will be
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CDAD: Clostridium-diﬃcile-associated disease
CDM: Chemically deﬁned media
CM: Conditioned media
CTFR: Cystic ﬁbrosis transmembrane
conductance regulator
ECN: E. coli Nissle 1917
EGFR: Epidermal growth factor receptor
EHEC: E. coli O157:H7
EPEC: Enteropathogenic E. coli
ERK: Extracellular-signal-regulated kinase
GSH: Glutathione
hBD: Human beta defensin
HSP: Heat shock proteins
IBD: Inﬂammatory bowel disease
IBS: Irritable bowel syndrome
IEC: Intestinal epithelial cell
IFN: Interferon
IL: Interleukin
IκB: Inhibitor of kappa B




LcS: Lactobacillus casei Shirota
LGG: Lactobacillus rhamnosus GG





MAPK: Mitogen-activated protein kinase
MCP: Monocyte chemotactic protein
NEC: Necrotizing enterocolitis
NF-κB: Nuclear factor kappa B
PKC: Protein kinase C
PPARγ: Peroxisome-proliferator-activated
receptor gamma
ROS: Reactive oxygen species
RXR: Retinoid X receptor
SAPK/JNK: Stress-activated protein kinase/c-Jun
NH2-terminal kinase
Sb: Saccharomyces boulardii
SOCS: Suppressor of cytokine signaling
TCR: T-cell receptor
TER: Transepithelial electrical resistance
TJs: Tight junctions
TLR: Toll-like receptor
TNF: Tumor necrosis factor
UC: Ulcerative colitis
UCB: Unconjugated bilirubin
VDR: Vitamin D receptor
ZO: Zonula occludens.
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